Uniqure NV (QURE) - Total Liabilities
Based on the latest financial reports, Uniqure NV (QURE) has total liabilities worth $659.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Uniqure NV cash flow conversion to assess how effectively this company generates cash.
Uniqure NV - Total Liabilities Trend (2010–2024)
This chart illustrates how Uniqure NV's total liabilities have evolved over time, based on quarterly financial data. Check QURE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Uniqure NV Competitors by Total Liabilities
The table below lists competitors of Uniqure NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Capital Clean Energy Carriers Corp.
NASDAQ:CCEC
|
USA | $2.67 Billion |
|
Ujjivan Small Finance Bank Limited
NSE:UJJIVANSFB
|
India | Rs457.80 Billion |
|
Yueyang Forest & Paper Co Ltd
SHG:600963
|
China | CN¥12.60 Billion |
|
Arafura Rare EARTHS Ltd
AU:ARU
|
Australia | AU$7.79 Million |
|
Magazine Luiza S.A
SA:MGLU3
|
Brazil | R$26.06 Billion |
|
Wuxi Xinhongtai ElecTech
SHG:603016
|
China | CN¥197.03 Million |
|
FGV Holdings Bhd
KLSE:5222
|
Malaysia | RM11.34 Billion |
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
China | CN¥594.22 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Uniqure NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Uniqure NV stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Uniqure NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Uniqure NV (2010–2024)
The table below shows the annual total liabilities of Uniqure NV from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $563.29 Million | -9.73% |
| 2023-12-31 | $624.02 Million | +172.55% |
| 2022-12-31 | $228.96 Million | +7.29% |
| 2021-12-31 | $213.40 Million | +121.17% |
| 2020-12-31 | $96.49 Million | -23.16% |
| 2019-12-31 | $125.57 Million | +33.16% |
| 2018-12-31 | $94.30 Million | -20.71% |
| 2017-12-31 | $118.93 Million | -6.08% |
| 2016-12-31 | $126.63 Million | -5.54% |
| 2015-12-31 | $134.06 Million | +109.18% |
| 2014-12-31 | $64.09 Million | +38.93% |
| 2013-12-31 | $46.13 Million | +479.87% |
| 2012-12-31 | $7.95 Million | -26.91% |
| 2011-12-31 | $10.88 Million | -9.52% |
| 2010-12-31 | $12.03 Million | -- |
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more